Tacrolimus capsules
Total Payments
$175,269
Transactions
11
Doctors
2
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $175,269 | 11 | 2 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $169,865 | 3 | 96.9% |
| Consulting Fee | $3,570 | 1 | 2.0% |
| Travel and Lodging | $1,712 | 5 | 1.0% |
| Education | $122.00 | 2 | 0.1% |
Payments by Type
Research
$169,865
3 transactions
General
$5,404
8 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Study Comparing Brand and Generic Immunosuppresion on Transplant Outcomes, Adherence, & Immune Response | Astellas US Technologies | $169,865 | 0 |
Ad
Manufacturing Companies
- Astellas US Technologies $169,865
- Astellas Pharma Inc $5,282
- Astellas Pharma Global Development $122.00
Product Information
- Type Drug
- Total Payments $175,269
- Total Doctors 2
- Transactions 11
About Tacrolimus capsules
Tacrolimus capsules is a drug associated with $175,269 in payments to 2 healthcare providers, recorded across 11 transactions in the CMS Open Payments database. The primary manufacturer is Astellas US Technologies.
Payment data is available from 2017 to 2017. In 2017, $175,269 was paid across 11 transactions to 2 doctors.
The most common payment nature for Tacrolimus capsules is "Unspecified" ($169,865, 96.9% of total).
Tacrolimus capsules is associated with 1 research study, including "Study Comparing Brand and Generic Immunosuppresion on Transplant Outcomes, Adherence, & Immune Response" ($169,865).